The Pandemic's Effect on Diagnosis and Treatment of Rectal Cancer

Rectal Cancer Clinical Trial

— CovidRC  

Official title:

An Analysis of Covid-19 Effect on Patients With Colorectal Cancer - Follow-up Regarding Tumour Stage, Neoadjuvant Treatment, Delay and Long-term Survival

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05328960
• Other study ID #: CovidRC
• Status: Recruiting
• Start date: February 15, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: December 2023
• Source: Sahlgrenska University Hospital, Sweden
• Contact: Eva Angenete, MD. PhD
• Phone: 0760514441
• Email: eva.angenete[@]vgregion.se
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Colorectal cancer is common with an annual prevalence of 6000. The majority can be cured and the five year survival rate is over 60%. In december 2019 reports came in about SARS-Cov-2, which later was named Covid-19. The World Health Organization classified it as a pandemic in March 2020. In Sweden the number of patients with Covid-19 increased mainly in the urban areas in March 2020. Care for patients with other diseases were affected and local changes from guidelines were adopted. In some regions and countries the indications for adjuvant and neoadjuvant treatment for colorectal cancer were somewhat changed. The number of patients diagnosed with colorectal cancer also decreased, as well as other types of cancer. The true effect on outcome with a delayed diagnosis remains unknown.

The aim of this study is to evaluate the effects of the Covid-19 pandemic on the diagnosis, treatment and survival of patients with colorectal cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 8000
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Rectal cancer diagnosis 2019-2022

Exclusion Criteria:

• No rectal cancer diagnosis 2019-2022

Related Conditions & MeSH terms

• Rectal Cancer
• Rectal Neoplasms

Intervention

Other:
• Diagnosed during or not during the pandemic
We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic

Locations

Country	Name	City	State
Sweden	Dept. of Surgery, Sahlgrenska University Hospital/Ostra	Gothenburg

Sponsors (1)

Lead Sponsor	Collaborator
Sahlgrenska University Hospital, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Yearly incidence of rectal cancer	The number of patients diagnosed yearly 2019, 2020, 2021 and 2022	2019-2022
Secondary	Symptoms at diagnosis	Symptoms at diagnosis as reported by patients	6 months prior diagnosis
Secondary	Patient's delay	Delay from symptoms until doctors appointment	12 months prior diagnosis
Secondary	Doctor's delay	Delay from doctor's appointment until diagnosis	12 months prior diagnosis
Secondary	Treatment changes	Any changes from the treatment plan due to covid-19	Diagnosis and 12 months following